前列腺癌新輔助內(nèi)分泌治療

前列腺癌新輔助內(nèi)分泌治療新輔助內(nèi)分泌治療(eaduathrneNHT或ntadoe-piainnADT內(nèi)分治療9年Mone報切除術(shù)前的輔助治療,結(jié)果顯示前列腺體積及腫瘤體積明顯減小,術(shù)中失血減少,手術(shù)時間縮短,發(fā)本在%的T0近0治是的直。列預(yù)前體A水平及Gleasn。助療腺治除前6月T前平小2（1而（3NHT能有效降漿PA（要等PA5為T能夠床2列腺癌分期，床T3期腫瘤NHT現(xiàn)即臨斷時的分期過所致6，7。緣可加列癌局復(fù)、處移死率與切NHT能顯著降低臨床T2期及以下前列腺癌的切緣陽性，8床T3期（0原因能是NHT導(dǎo)致前列，不陽此T卻的esn但究可種。么T治療能否床3行T治？腺組在20年道了2例T2-00期癌患隨果中T有2例患者予3個雄阻斷治療（戈+氟訪4年。結(jié)果顯示管NHT組(純術(shù)組)atlgialowsai15%v7%,p<0.0床T2是T3（c2p00;3,001化義(P=0.18)對床T2分時,HT高(3/102s,=),床3組統(tǒng)義(7s21/95,p=0.)示NHT治床T2對3（1。6，Hsu等報道235例臨床T3a期（2中NHT組5例組0的5床P（prgesnfesurvia分別為43.和77.6%后者的別為59.5%和95.前者的腫瘤特異生存cuv,CSS）和總體率(llsvl,OS)分別為88.7%和79.8為98.%和95.9%為33.和57.1明T療和照組(純組)間5CS:p=.2;O:p=.1r等對176例臨床T3為NHT益疾。.LupronDepotNeoadjuvantProstateCancerGroup多中心前瞻性隨對床Tb期前列腺現(xiàn)NHT組（3+氟5生<與照無顯差68%s676,p=0.663。（13）1年r756中0例受了T療,為8月比間有,現(xiàn)NT過3者低化,Gee等(14)者NHT治療8,手療訪5年其較。2年瑞典的隨機(jī)對照研究中5，6例局限性癌中NHT和純手術(shù)各半以T2a期治切緣陽性率差異顯著，分別為45.5和23.6%（p=0.016。但是無生化進(jìn)展生存率（PSA<0.5ng/m與無差分為49.8和51.5%（p08。在最（16有2474列腺癌中NHT組1083例，單純近距離放射組1391間48隨（73T和的aaemoratACM（p4≥3歲中T的ACM加調(diào)危比14，9區(qū)間1013，1。究助者年3，以及可逆性的認(rèn)知障礙等，而且新輔助內(nèi)分泌治療對生存期改善不明顯，尤其是對于臨床T3床2，隨著新輔助治療時間延長至超過3個。獻(xiàn)u,gXH,u,etal.Compraivesyoftheimpactof32versus82mothnoajvathomnlyonoeoflpaocpcraial.JCancersClnOncl,207,133(8:555-562.2.Hsu,JoniauS.CoprgreslsafersyinpatetswhclilunilterlT3aprostatecancertreatedwithorwithoutneoadjuvantandrogen-deprivationtherapy.BJUInt,2006,9):11-..BrnsdtS,chC,HmM,etal.N-tnHthayadlprostatectomy:effectsontumorousandbenigntissuevolumes-amorphometricstudy.UrolRes,197,25(1:43-47.4.GlaeME,GolenegSL,JonsEC,etal.Bicemclandpatooiclefetsof8motsofnoutanroenwiraltrybeforeraialyinpatintswhcilyoidpoaeae.Jrl,9,551:13-1.5.LodG,hsnC,Kin,et.SAelsdteaefpiesgalrnsnrdclpyscnsprcdedyanroenbeinclialB(bxo)pottecacr.TheLupronDepotNeoadjuvantStudyGroup.Urology,1997,49(3ASuppl):70-73.6.TunnUW.Neo-adjuvanthormonaltherapyofprostatecancer.UrolRes,1997,25Suppl2:S57-S6.7.LabrieF,DupontA,CusanL,etal.Downstagingoflocalizedprostatecancerbyneoadjuvantywithfltmieandlupon:theftctldadrdta.ClinInstM,193,16(6):499-50.8.Mr,BaitiI,BédardC,etal.Durationofneodjvntanrgendpvintheraybeforerdclpratyaddisease2freesurialinnwithprsate.,201,58(2Suppl1):71-77.9.DebruyneFM,WitjesWP.Neoadjuvanthormonaltherapypriortoradicalprostatectomy:theEuoenexpeine.MolUrl,200,4(3):251-25;disuson25710.PetrakiCD,SfikasCP.Histopathologicalchangesinducedbytherapiesinthebenignprostateadprotteaencriom.HisolHsopto,207,22(1:107–8.SnCC,Derye,Fr,etal.rfolo-upresultsofaErenprospectiverandomizedstudyonneoadjuvanthormonaltherapypriortoradicalprostatectomyinT2-3N0M0prostatecancer.EuropeanStudyGrouponNeoadjuvantTreatmentofProstateCancer.EurUro,2000,38(6):706-713.12.CavrBS,BinoJJ,Scardino,eta.Lmoutcmefollwingrdclpsemynmnwthnalge3pstenr.Jo,0,162:6581.y,Pareek,ShrfiR,etal.NetandrgnabltonbferaialprostatectomyincT2bNxM0prostatecancer:5-yearresults.LupronDepotNeoadjuvantProstatearyu.J,0,7,6.14.GleaveME,LaBiancaSE,GoldenbergSL,etal.Long-termneoadjuvanthormonetherapypriortoradicalprostatectomy:evaluationofriskforbiochemicalrecurrenceat5-yearfollow-up.,,6:9–.15.AbrahamssonGP,Ahlgren,HugossonJ,etal.Three-monthneoadjuvanthormonetherapybeforeradicalprostatectomy:a7-yearfollow-upofarandomizedcontrolledtrail.BJUInt,2002,90,561-5